NCT05387681 is a Phase 2 clinical trial of Envafolimab in Gastric/Gastroesophageal Junction Adenocarcinoma, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT05387681?

Interventions in NCT05387681: Envafolimab.

What condition does NCT05387681 study?

NCT05387681 studies Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy.

Is NCT05387681 still recruiting?

NCT05387681 is currently status unknown. Last updated 24 May 2022.

Last reviewed 2022-05-24 · How we verify

NCT05387681

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric

Status unknown Phase 2 Last updated 24 May 2022

What this trial tests

Phase 2 trial testing Envafolimab in Gastric/Gastroesophageal Junction Adenocarcinoma in 35 participants. Status unknown.

Timeline

30 May 2022

Primary endpoint
30 July 2023

30 December 2025

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	30 May 2022
Primary completion	30 July 2023
Estimated completion	30 December 2025

Drugs / interventions tested

Envafolimab — full drug profile →

Conditions studied

Gastric/Gastroesophageal Junction Adenocarcinoma — all drugs for Gastric/Gastroesophageal Junction Adenocarcinoma →
Radiotherapy — all drugs for Radiotherapy →
Immunotherapy — all drugs for Immunotherapy →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 75, any sex, with Gastric/Gastroesophageal Junction Adenocarcinoma or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, exploratory clinical study to evaluate the efficacy and safety of Preoperative short course radiotherapy with Envafolimab, Endostatin and SOX regimen in resectable locally advanced gastric/gastroesophageal junction adenocarcinoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research.
Kumar R, Kim J, Deek MP, Eskander MF, et al · · 2023 · cited 7× · PMID 37504333 · DOI 10.3390/curroncol30070473
Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment.
Yuan M, Zhai Y, Hui Z. · · 2022 · cited 4× · PMID 36439496 · DOI 10.3389/fonc.2022.978608

Verify or expand the search:

Other trials of Envafolimab

Trials testing the same drug.

NCT06959693 — A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients Wit · Phase 2, PHASE3 · not yet recruiting
NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT07260305 — A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima · Phase 1 · recruiting
NCT06618391 — Local Injection and Systemic Therapy in the Treatment of NSCLC. · Phase 2 · not yet recruiting
NCT06663007 — RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure · Phase 1, PHASE2 · recruiting

Other recruiting trials for Gastric/Gastroesophageal Junction Adenocarcinoma

Currently open trials in the same condition.

NCT06415669 — A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma · Phase 2 · recruiting
NCT06774222 — A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG · Phase 2 · recruiting
NCT04895709 — A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid · Phase 1, PHASE2 · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05387681 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 24 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05387681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing